<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ORPHENADRINE CITRATE, ASPIRIN AND CAFFEINE- orphenadrine citrate, aspirin and caffeine tablet, multilayer </strong><br>Rebel Distributors Corp<br></p></div>
<h1>Orphenadrine Citrate, Aspirin and Caffeine Tablets</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_59ebf8fc-0164-4553-a220-092c13f865f7"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Each tablet, for oral administration, contains Orphenadrine Citrate USP, 25 mg or 50 mg, Aspirin USP, 385 mg or 770 mg, Caffeine USP, 30 mg or 60 mg.</p>
<p>Orphenadrine citrate, <span class="Italics">N</span>, <span class="Italics">N</span>-Dimethyl-2-[(o-methyl-α-phenylbenzyl)oxy]ethylamine citrate (1:1), is a centrally acting (brain stem) compound. It occurs as a white, practically odorless, crystalline powder, having a bitter taste. Its molecular formula is C<span class="Sub">18</span>H<span class="Sub">23</span>NO.C<span class="Sub">6</span>H<span class="Sub">8</span>O<span class="Sub">7</span> with a molecular weight of 461.51. The structural formula is shown below.</p>
<div class="Figure"><img alt="Orphenadrine Citrate Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8e41b33e-f71f-4a5e-b88f-cdfefb2bee20&amp;name=8e41b33e-f71f-4a5e-b88f-cdfefb2bee20-01.jpg"></div>
<p>Aspirin, salicylic acid acetate, is a non-opiate analgesic, anti-inflammatory and antipyretic agent. It occurs as a white, crystalline tabular or needle like powder and is odorless or has a <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span> odor. Its molecular formula is C<span class="Sub">9</span>H<span class="Sub">8</span>O<span class="Sub">4</span>, with a molecular weight of 180.16. The structural formula is shown below.</p>
<div class="Figure"><img alt="Aspirin Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8e41b33e-f71f-4a5e-b88f-cdfefb2bee20&amp;name=8e41b33e-f71f-4a5e-b88f-cdfefb2bee20-02.jpg"></div>
<p>Caffeine, 1,3,7-trimethylxanthine, is a central nervous system stimulant which occurs as a white powder or white glistening needles. It also has a bitter taste. Its molecular formula is C<span class="Sub">8</span>H<span class="Sub">1</span><span class="Sub">0</span>N<span class="Sub">4</span>O<span class="Sub">2</span>, with a molecular weight of 194.19. The structural formula is shown below.</p>
<div class="Figure"><img alt="Caffeine Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8e41b33e-f71f-4a5e-b88f-cdfefb2bee20&amp;name=8e41b33e-f71f-4a5e-b88f-cdfefb2bee20-03.jpg"></div>
<p>Each tablet contains the following inactive ingredients: colloidal silicon dioxide, corn starch, croscarmellose sodium, FD&amp;C Blue No. 1, FD&amp;C Yellow No. 10, anhydrous lactose, microcrystalline cellulose, povidone, pregelatinized starch, stearic acid, and sodium lauryl sulfate.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_9fc312d8-53fa-4ab7-b589-15ed8eade9aa"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Orphenadrine citrate is a centrally acting (brain stem) compound which in animals selectively blocks facilitatory functions of the reticular formulation. Orphenadrine does not produce myoneural block, nor does it affect crossed extensor reflexes. Orphenadrine prevents nicotine-induced <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> but not those produced by strychnine.</p>
<p>Chronic administration of Orphenadrine Citrate, Aspirin, and Caffeine to dogs and rats has revealed no drug-related toxicity. No blood or urine changes were observed, nor were there any macroscopic or microscopic pathological changes detected. Extensive experience with combinations containing aspirin and caffeine has established them as safe agents. The addition of orphenadrine citrate does not alter the toxicity of aspirin and caffeine.</p>
<p>The mode of therapeutic action of orphenadrine has not been clearly identified, but may be related to its analgesic properties. Orphenadrine citrate also possesses anticholinergic actions.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_6990c381-836a-4b05-86bd-8a43664d8ccf"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<ol>
<li>Symptomatic relief of mild to moderate <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> of acute <span class="product-label-link" type="condition" conceptid="4244662" conceptname="Disorder of musculoskeletal system">musculoskeletal disorders</span>.</li>
<li>The orphenadrine component is indicated as an adjunct to rest, physical therapy, and other measures for the relief of <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> associated with acute painful musculoskeletal conditions.<p class="First">The mode of action of orphenadrine has not been clearly identified, but may be related to its analgesic properties. Orphenadrine Citrate, Aspirin, and Caffeine Tablets do not directly relax <span class="product-label-link" type="condition" conceptid="4136244" conceptname="Feeling tense">tense</span> skeletal muscles in man.</p>
</li>
</ol>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_f57faf77-9452-4237-8105-3d115cf88277"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Because of the mild anti-cholinergic effect of orphenadrine, Orphenadrine Citrate, Aspirin, and Caffeine Tablets should not be used in patients with <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, pyloric or duodenal obstruction, achalasia, <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span>, or obstructions at the bladder neck. Orphenadrine Citrate, Aspirin, and Caffeine Tablets are also contraindicated in patients with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> and in patients known to be sensitive to aspirin or caffeine.</p>
<p>The drug is contraindicated in patients who have demonstrated a previous <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the drug.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_bcfc8a13-21a9-4f3a-a27c-767ab19e8de3"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Reye’s Syndrome may develop in individuals who have chicken pox, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>, or <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">flu symptoms</span>. Some studies suggest possible association between the development of Reye’s Syndrome and the use of medicines containing salicylate or aspirin. Orphenadrine Citrate, Aspirin, and Caffeine Tablets contain aspirin and therefore are not recommended for use in patients with chicken pox, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>, or <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">flu symptoms</span>. Orphenadrine Citrate, Aspirin, and Caffeine Tablets may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle: ambulatory patients should therefore be cautioned accordingly. </p>
<p>Aspirin should be used with extreme caution in the presence of <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcers</span> and coagulation abnormalities.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c764c3a4-0bd3-453f-8f0f-cc654653d032"></a><a name="section-5.1"></a><p></p>
<h2>Usage in Pregnancy</h2>
<p class="First">Since safety of the use of this preparation in pregnancy, during lactation, or in the child-bearing age has not been established, use of the drug in such patients requires that the potential benefits of the drug be weighed against its possible hazard to the mother and child.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d625486b-7bdd-4014-924c-02fa6ec76729"></a><a name="section-5.2"></a><p></p>
<h2>Usage in Children</h2>
<p class="First">The safe and effective use of this drug in children has not been established. Usage of this drug in children under 12 years of age is not recommended.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_3cf30d74-5085-4915-b3a2-d92d3fce51ed"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span> have been reported in a few patients receiving propoxyphene and orphenadrine concomitantly. As these symptoms may be simply due to an additive effect, reduction of dosage and/or discontinuation of one or both agents is recommended in such cases.</p>
<p>Safety of continuous long term therapy with Orphenadrine Citrate, Aspirin, and Caffeine Tablets has not been established; therefore, if Orphenadrine Citrate, Aspirin, and Caffeine Tablets are prescribed for prolonged use, periodic monitoring of blood, urine and liver function values is recommended.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_c1fabf40-ff6c-486b-ae82-adc2904030a1"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Side effects of Orphenadrine Citrate, Aspirin, and Caffeine Tablets are those seen with aspirin and caffeine or those usually associated with mild anticholinergic agents. These may include <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="201688" conceptname="Delay when starting to pass urine">urinary hesitancy</span> or retention, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, dilation of the pupil, increased intraocular <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, and rarely, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> and other dermatoses. Infrequently, an elderly patient may experience some degree of <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>. Mild central excitation and occasional <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> may be observed. These mild side effects can usually be eliminated by reduction in dosage. One case of <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span> associated with the use of Orphenadrine Citrate, Aspirin, and Caffeine Tablets has been reported. No causal relationship has been established. Rare G.I. <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> due to aspirin content may be associated with the administration of Orphenadrine Citrate, Aspirin, and Caffeine Tablets. Some patients may experience transient episodes of <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_d1f02050-b61e-49d0-b10a-ca92d238918d"></a><a name="section-8"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Orphenadrine Citrate, Aspirin, and Caffeine Tablets, 25 mg/385 mg/30 mg: Adults 1 to 2 tablets 3 to 4 times daily. </p>
<p>Orphenadrine Citrate, Aspirin, and Caffeine Tablets, 50 mg/770 mg/60 mg: Adults 1/2 to 1 tablet 3 to 4 times daily.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_7aab12e3-038a-4f3c-9f50-30c44d8dcafd"></a><a name="section-9"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Orphenadrine Citrate, Aspirin, and Caffeine Tablets, 50 mg/770 mg/60 mg are scored, capsule-shaped, layered tablets colored white and green, imprinted SZ 491 and are supplied as:</p>
<p>NDC 21695-726-30 bottles of 30</p>
<p>NDC 21695-726-45 bottles of 45</p>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_16a3184a-1780-4c76-9ada-71096d2c6c30"></a><a name="section-9.1"></a><p></p>
<h2>Storage</h2>
<p class="First">Store at 20°-25°C (68°-77° F) (see USP Controlled Room Temperature).</p>
<p>Protect from moisture.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_524a4227-3ce8-49b5-8158-4c80c5c71a8d"></a><a name="section-10"></a><p></p>
<p class="First">Sandoz Inc.</p>
<p>Princeton, NJ 08540</p>
<p>Repackaged by:</p>
<p>Rebel Distributors Corp</p>
<p>Thousand Oaks, CA 91320</p>
<br>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_ba444c47-8b07-4088-86a3-65cbe3a78e4e"></a><a name="section-11"></a><p></p>
<h1>50 mg/770 mg/60 mg Label</h1>
<p class="First">Orphenadrine</p>
<p>Citrate, Aspirin,</p>
<p>and Caffeine</p>
<p>Tablets</p>
<p>50 mg/770 mg/60 mg</p>
<p>Rx only</p>
<div class="Figure">
<img alt="Orphenadrine/Aspirin/Caffeine 50/770/60mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8e41b33e-f71f-4a5e-b88f-cdfefb2bee20&amp;name=8e41b33e-f71f-4a5e-b88f-cdfefb2bee20-04.jpg"><p class="MultiMediaCaption"></p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ORPHENADRINE CITRATE, ASPIRIN AND CAFFEINE 		
					</strong><br><span class="contentTableReg">orphenadrine citrate, aspirin and caffeine tablet, multilayer</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:21695-726(NDC:0185-0714)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ORPHENADRINE CITRATE</strong> (ORPHENADRINE) </td>
<td class="formItem">ORPHENADRINE CITRATE</td>
<td class="formItem">50 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>ASPIRIN</strong> (ASPIRIN) </td>
<td class="formItem">ASPIRIN</td>
<td class="formItem">770 mg</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CAFFEINE</strong> (CAFFEINE) </td>
<td class="formItem">CAFFEINE</td>
<td class="formItem">60 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE, GREEN</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">2mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">SZ491</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:21695-726-30</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:21695-726-45</td>
<td class="formItem">45  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA074654</td>
<td class="formItem">12/31/1996</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Rebel Distributors Corp
							(118802834)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Rebel Distributors Corp</td>
<td class="formItem"></td>
<td class="formItem">118802834</td>
<td class="formItem">RELABEL, REPACK</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>8e41b33e-f71f-4a5e-b88f-cdfefb2bee20</div>
<div>Set id: 8e41b33e-f71f-4a5e-b88f-cdfefb2bee20</div>
<div>Version: 1</div>
<div>Effective Time: 20101022</div>
</div>
</div> <div class="DistributorName">Rebel Distributors Corp</div></p>
</body></html>
